Comparing reactivation and retreatment for three doses of bevacizumab in type 1 retinopathy of prematurity

To determine timing and rates of reactivation and retreatment of type 1 retinopathy of prematurity (ROP) after treatment with either 0.125 mg, 0.250 mg, or 0.500 mg of intravitreal bevacizumab (IVB).

Source: Journal of AAPOS - March 6, 2024 Category: Opthalmology Authors: Jay Chopra, Kathryn M. Haider, Charline S. Boente Tags: Major Article Source Type: research